RAPT Therapeutics, Inc.
RAPT
$11.32
$0.5955.55%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 7.55% | -6.64% | 24.11% | -6.51% | -0.48% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -33.40% | -40.76% | 63.97% | -41.66% | 3.41% |
| Operating Income | 33.40% | 40.76% | -63.97% | 41.66% | -3.41% |
| Income Before Tax | 36.22% | 43.76% | -72.46% | 41.25% | -9.43% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 36.22% | 43.76% | -72.46% | 41.25% | -9.43% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 36.22% | 43.76% | -72.46% | 41.25% | -9.43% |
| EBIT | 33.40% | 40.76% | -63.97% | 41.66% | -3.41% |
| EBITDA | 33.48% | 40.96% | -64.70% | 41.98% | -3.31% |
| EPS Basic | 88.50% | 89.92% | -41.79% | 42.07% | -7.91% |
| Normalized Basic EPS | 88.50% | 89.84% | -37.74% | 42.07% | -7.91% |
| EPS Diluted | 88.50% | 89.92% | -41.79% | 42.07% | -7.91% |
| Normalized Diluted EPS | 88.50% | 89.84% | -37.74% | 42.07% | -7.91% |
| Average Basic Shares Outstanding | 454.72% | 457.69% | 21.63% | 1.42% | 1.40% |
| Average Diluted Shares Outstanding | 454.72% | 457.69% | 21.63% | 1.42% | 1.40% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |